Premium
Tracheo–bronchial adenoid cystic carcinoma: A retrospective study
Author(s) -
Ning Ye,
He Wenxin,
Bian Dongliang,
Xie Dong,
Jiang Gening
Publication year - 2019
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.13162
Subject(s) - medicine , adenoid cystic carcinoma , bronchus , surgery , pathological , retrospective cohort study , radiation therapy , adenoid , complication , survival rate , carcinoma , respiratory tract , main bronchus , bronchoscopy , radiology , respiratory disease , respiratory system , lung
Objectives Adenoid cystic carcinoma (ACC) of the trachea and bronchus is rare, representing 1% of all respiratory tract cancers. We presented our experiences in treating tracheal–bronchial ACC and the results of long‐term surveillance. Methods We conducted a retrospective study of treating tracheo–bronchial ACC. From 2009 to 2014, 42 patients presented to our department. All of them received surgical resection and adjunctive therapy. Results R0 resections were achieved in 33 patients, whereas 15 patients whose lesions spread outside the tracheo–bronchial lumens. Nine patients had R1 resections followed by radiation and chemotherapy. The 5 year survival rate of R1 resection group showed no difference compared to the R0 resection group, but the 5 year disease‐free survival rate showed difference in extra‐lumenal invasion (ELI) and non‐ELI group ( P = 0.0357 < 0.05), although no difference was seen in the overall survival rate in these two groups. Conclusions ACC of the trachea and bronchus is a rare and low‐to‐moderate grade malignant tumor. When the R0 resection is over risky or may cause mortal complication, the R1 resection with adjunctive therapy is acceptable for patients to obtain a promising prognosis, whereas pathological ELI is an adverse prognostic indicator.